Last reviewed · How we verify
CAB-LA Loading Dose
CAB-LA is a long-acting injectable formulation of cabotegravir, an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase to prevent viral replication.
CAB-LA is a long-acting injectable formulation of cabotegravir, an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase to prevent viral replication. Used for HIV-1 infection in treatment-naive and treatment-experienced adults (as part of combination antiretroviral therapy).
At a glance
| Generic name | CAB-LA Loading Dose |
|---|---|
| Also known as | Cabotegravir Long-Acting Injectable |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Cabotegravir inhibits HIV integrase, the viral enzyme responsible for inserting HIV DNA into the host cell genome. The long-acting (LA) formulation provides sustained drug release over several weeks or months via intramuscular injection, enabling less frequent dosing compared to daily oral antiretrovirals. The loading dose establishes therapeutic plasma concentrations rapidly before transition to maintenance dosing.
Approved indications
- HIV-1 infection in treatment-naive and treatment-experienced adults (as part of combination antiretroviral therapy)
Common side effects
- Injection site reactions (pain, induration, erythema)
- Headache
- Fatigue
- Nausea
- Diarrhea
- Pyrexia
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
- The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE (PHASE3)
- Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 (PHASE2)
- A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (PHASE2)
- Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study (PHASE2)
- A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (PHASE3)
- Long-Acting Treatment in Adolescents (LATA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: